Pilot dose-response trial of I.V. ketamine in treatment-resistant depression
Date
2014
Authors
Lai, R.
Katalinic, N.
Glue, P.
Somogyi, A.
Mitchell, P.
Leyden, J.
Harper, S.
Loo, C.
Editors
Advisors
Journal Title
Journal ISSN
Volume Title
Type:
Journal article
Citation
World Journal of Biological Psychiatry, 2014; 15(7):579-584
Statement of Responsibility
Rosalyn Lai, Natalie Katalinic, Paul Glue, Andrew A. Somogyi,
Philip B. Mitchell, John Leyden, Simon Harper, and Colleen K. Loo
Conference Name
Abstract
OBJECTIVES: Research studies have reported impressive antidepressant effects with ketamine but significant knowledge gaps remain over the best method of administering ketamine, and the relationships between dose, antidepressant response and adverse effects. METHODS: In this pilot dose-finding study, the efficacy and tolerability of ketamine given by rapid intravenous (i.v.) infusion were assessed in a double-blind, placebo-controlled, crossover design, in four subjects with treatment- resistant depression. Each subject received up to four i.v. doses of ketamine (0.1, 0.2, 0.3, 0.4 mg/kg), given over 2-5 min, 1 week apart, and one randomly inserted placebo treatment. RESULTS: Three of four subjects achieved antidepressant response (≥ 50% decrease in Montgomery-Asberg Depression Rating Scale scores), two at the minimum 0.1 mg/kg dose, though all relapsed within a week. For two subjects, the greatest improvement occurred at the highest dose received. Rapid infusion over 2 min led to significant adverse psychotomimetic effects which also increased proportionately with ketamine dosage. CONCLUSIONS: This is the first trial to present dose-response data of ketamine efficacy and psychomimetic effects in depressed subjects. Antidepressant efficacy may be dose-related. Psychotomimetic effects were dose-related. Rapid infusion over 2 min may not be a feasible clinical approach to treatment, given poor tolerability.
School/Discipline
Dissertation Note
Provenance
Description
Access Status
Rights
© 2014 Informa Healthcare